Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis

摘要: Abstract Context The process of care for patients with prostate cancer is subject to different degrees uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool the cell cycle progression (CCP) score. Objective This systematic review assesses evidence on value CCP instrument in treatment by reviewing current publications integrating results via a meta-analysis. Evidence acquisition We performed Medline Embase April 2014, according Preferred Reporting Items Systematic Review Meta-analysis (PRISMA). Unpublished studies were retrieved 2013–2014 proceedings major conferences field. Sixteen selected inclusion. synthesis show that use score better than existing assessments at elucidating aggressive potential an individual. pooled hazard ratio biochemical recurrence per 1-unit increase was 1.88 univariate model 1.63 multivariate model. Four showed testing can impact decisions physicians regarding treatment, potentially lead decrease surgical interventions low-risk patients. Conclusions offers comprehensive overview testing, provides clinicians, patients, policy makers strong summary measure its validity clinical utility. It will be important develop economic such technology health systems. Patient In this paper, we related cancer. found good suggesting improves prognosis, valuable treating benefits are yet studied.